efpia

CLINICAL TRIALS STRATEGY

EFPIA Vision for 2030+

EFPIA Vision for Clinical Trials: 2030 and Beyond

Our vision is to re-establish a highly competitive environment for global clinical trials in Europe – one that facilitates **faster, smarter, and more patient-centric trials.**

Together with other stakeholders, we are committed to closing the gap between Europe and other regions, reversing the erosion of innovation, and enabling early access to cutting-edge treatments.

We envision a future where Europe is at the forefront of pioneering research, improving healthcare outcomes, and enriching the lives of patients in Europe and around the globe.

Clinical Trial Strategy in a Snapshot



Faster

Smarter

More Patient-centric

Clinical Trial Strategy in a Snapshot

Faster

Focusing on what really matters.

Keywords

#Breaking down the barriers #shorter process steps #simplifications #KPIs #harmonisation #streamlined processes #optimisation #operational excellence

Focused areas

- **Advocate** for EU CT legislation that facilitates the start-up and conduct of CTs and does not raise any barriers.
- **Ensure** improved, well-functioning system(s) and their interoperability.
- **Strengthen** cooperation with stakeholders and address current gaps, e.g., with Ethics Committees, academia, regulators.
- **Promote** and facilitate interaction among all relevant parties.
- **Promote** and contribute to an iterative, integrated process, with seamless multistakeholder involvement.
- **Strive** to reduce administrative burden across the end-to-end process.
- **Facilitate** and promote the establishment of a platform for open multi-stakeholder dialogue, to share and learn from experiences while seeking common solutions.

Smarter

Prepared for the opportunities of today – and tomorrow.

#New technologies #new methodologies #preparing for the future #incentives #learning #trainings

- **Prepare** for the clinical environment & healthcare systems of 2030 and beyond.
- **Improve and accelerate** processes for the validation, acceptance and adoption of: (1) new trial methodologies (2) emerging technologies, e.g. decentralised elements in trials, blockchain, digitalisation, and artificial intelligence.
- **Aligning, educating, and preparing** the ecosystem on critical innovations to identify solutions and ensure rapid adoption by all stakeholders.
- **Ensure** connectivity between future methods and technologies and the legislative environment, e.g., CTR/IVDR/MDR interface.
- **Better access** to data & secondary use of data (e.g. RWD/RWE).

More Patient-centric

Patients at the heart of research.

#Raising awareness #access to information #building trust #inclusiveness #early involvement #diversity

- **Focus** more on patient outcomes, aiming for a pan-European approach to foster trust.
- **Enhance** cooperation with patients' organisations, for a better understanding of their challenges and to provide required trainings, including on new methodologies and technologies.
- **Jointly, raise awareness** on the importance of clinical trials to patients and HCPs.
- **Improve** access to information on (available) clinical trials.
- **Optimise** the way clinical research is conducted and respectful of the patient resource (e.g. embed in the clinical practice). Accept diverse evidence sources for multiple uses (e.g. EHR)
- **Improve** access to clinical trials (e.g., enable cross-boarded access), increase flexibility and diversity.